Literature DB >> 4376658

Human chorionic gonadotropin as a tumor marker.

J L Vaitukaitis.   

Abstract

Ectopic production and secretion of hormones by a wide variety of tumors has been known for decades. Initially, ectopic hormone secretion was recognized by signs and symptoms of excess circulating biologically active hormone. With development of more sophisticated assay techniques, biologically inactive fragments and "big" forms of authentic hormones have been identified in these syndromes. Recently, a specific hCG assay has been developed for selectively measuring hCG in plasma samples containing both hLH and hCG. Studies reported to date suggest that hCG may be a good tumor marker. Using that assay system, several hundred sera obtained from patients with a wide variety of tumors were screened. Patients with tumors of the stomach, liver, ovary and testis were found to have the highest incidence of ectopic hCG secretion.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4376658

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  6 in total

Review 1.  Hormone-producing tumors of the ovary.

Authors:  Ara Chalvardjian
Journal:  Endocr Pathol       Date:  1990-09       Impact factor: 3.943

2.  A positive pregnancy test in the post-menopausal psychiatric patient-: what to think?

Authors:  Imad Bashir; Kenneth Ihenetu; James J Miller; Min-Hye Gim; Steven Lippmann
Journal:  Psychiatry (Edgmont)       Date:  2006-02

3.  Evidence for a gonadotropin from nonpregnant subjects that has physical, immunological, and biological similarities to human chorionic gonadotropin.

Authors:  H C Chen; G D Hodgen; S Matsuura; L J Lin; E Gross; L E Reichert; S Birken; R E Canfield; G T Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1976-08       Impact factor: 11.205

4.  Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer.

Authors:  Miriam Lenhard; Alexandra Tsvilina; Lan Schumacher; Markus Kupka; Nina Ditsch; Doris Mayr; Klaus Friese; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-01-03       Impact factor: 4.430

5.  [New findings in the field of paraneoplastic syndromes].

Authors:  C Laroche; A Boissonnas; J R Maury
Journal:  J R Coll Physicians Lond       Date:  1979-07

6.  Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Authors:  Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.